Overview
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
Eligibility
Inclusion Criteria:
- Planned neoadjuvant chemotherapy
- Triple negative breast cancer
Exclusion Criteria:
- HER2-positive breast cancer
- Hormone receptor positive breast cancer